Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893340 | 0.80 | MAPT (0.39) | SLC6A3LMNA | |
| SCHEMBL22431621 | 0.78 | MAPT (0.38) | SLC6A3LMNAKCNH2 | |
| SCHEMBL19504086 | 0.75 | MAPT (0.38) | SLC6A3LMNA | |
| SCHEMBL18935670 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL18893472 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL24826336 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL28293350 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL24919515 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL18937936 | 0.69 | LMNA (0.37) | SLC6A3LMNACA2 | |
| SCHEMBL13858984 | 0.69 | TLR7 (0.41) | GPR84CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | SLC6A3 236/4885DRD2 4309/4885HTR2A 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.